Bioverativ Inc Stock

Stocks

27/04/18	Sanofi : sees new acquisitions and drugs reviving growth	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
15/02/18	Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	RE
07/02/18	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
30/01/18	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
23/01/18	Stocks hit record as senators reach deal to end shutdown	RE
22/01/18	Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	RE
22/01/18	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
22/01/18	Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

06/03/18	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
14/02/18	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
14/02/18	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
24/01/18	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
24/01/18	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR

29/03/18	Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
08/03/18	Sanofi finalise l'acquisition de Bioverativ
08/03/18	Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
23/02/18	Sanofi : franchit une étape dans son offre sur Bioverativ
07/02/18	Sanofi: Amélioration attendue en 2018 plus lente que prévu

Manager	Title	Age	Since
Brian Foard PSD	President	-	-
Timothy Harris PRN	Corporate Officer/Principal	76	01/02/2017
Joann Nestor SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Philippe Sauvage BRD	Director/Board Member	49	08/03/2018
Brian Foard BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOVERATIV INC	-.--%	+0.30%	-	-	0
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+91.62%	69.54B
ARGENX SE	-1.94%	+1.55%	+44.87%	+88.81%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	-4.17%	-0.12%	+34.91%	+9.94%	26.51B
INSMED INCORPORATED	-2.35%	-5.75%	-12.90%	+436.87%	25.89B
BIONTECH SE	-8.37%	-12.43%	+2.08%	-18.39%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+429.04%	20.22B
GENMAB A/S	-1.30%	+0.66%	+29.66%	-19.43%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.48%	-4.93%	+2.30%	+549.93%	15.69B
EXELIXIS, INC.	-1.47%	+0.68%	+45.51%	+142.00%	13.49B
Average	-2.55%	-1.93%	+53.54%	+190.04%	31.33B
Weighted average by Cap.	-2.63%	-1.50%	+50.25%	+149.23%